These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27858752)

  • 21. Pharyngeal pathology in a mouse model of oculopharyngeal muscular dystrophy is associated with impaired basal autophagy in myoblasts.
    Zhang Y; Zeuthen C; Zhu C; Wu F; Mezzell AT; Whitlow TJ; Choo HJ; Vest KE
    Front Cell Dev Biol; 2022; 10():986930. PubMed ID: 36313551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD.
    Impagliazzo A; Tepper AW; Verrips TC; Ubbink M; van der Maarel SM
    FEBS Lett; 2010 Apr; 584(8):1558-64. PubMed ID: 20226184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
    Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
    Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
    Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
    Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
    Chartier A; Benoit B; Simonelig M
    EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
    Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
    Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death.
    Fan X; Dion P; Laganiere J; Brais B; Rouleau GA
    Hum Mol Genet; 2001 Oct; 10(21):2341-51. PubMed ID: 11689481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.
    Nishii YS; Noto YI; Yasuda R; Kitaoji T; Ashida S; Tanaka E; Minami N; Nishino I; Mizuno T
    BMC Neurol; 2021 Jul; 21(1):265. PubMed ID: 34225694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis.
    Chartier A; Klein P; Pierson S; Barbezier N; Gidaro T; Casas F; Carberry S; Dowling P; Maynadier L; Bellec M; Oloko M; Jardel C; Moritz B; Dickson G; Mouly V; Ohlendieck K; Butler-Browne G; Trollet C; Simonelig M
    PLoS Genet; 2015 Mar; 11(3):e1005092. PubMed ID: 25816335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging.
    Anvar SY; Raz Y; Verway N; van der Sluijs B; Venema A; Goeman JJ; Vissing J; van der Maarel SM; 't Hoen PA; van Engelen BG; Raz V
    Aging (Albany NY); 2013 Jun; 5(6):412-26. PubMed ID: 23793615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
    van der Sluijs BM; van Engelen BG; Hoefsloot LH
    Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transcriptional regulation of Pabpn1 by the RNA binding protein HuR.
    Phillips BL; Banerjee A; Sanchez BJ; Di Marco S; Gallouzi IE; Pavlath GK; Corbett AH
    Nucleic Acids Res; 2018 Sep; 46(15):7643-7661. PubMed ID: 29939290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle.
    Apponi LH; Corbett AH; Pavlath GK
    Skelet Muscle; 2013 Oct; 3(1):23. PubMed ID: 24083404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.
    Chartier A; Raz V; Sterrenburg E; Verrips CT; van der Maarel SM; Simonelig M
    Hum Mol Genet; 2009 May; 18(10):1849-59. PubMed ID: 19258344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
    Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
    Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The small compound Icerguastat reduces muscle defects in oculopharyngeal muscular dystrophy through the PERK pathway of the unfolded protein response.
    Naït-Saïdi R; Chartier A; Abgueguen E; Guédat P; Simonelig M
    Open Biol; 2023 Apr; 13(4):230008. PubMed ID: 37042114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
    Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy.
    Davies JE; Rubinsztein DC
    Hum Mol Genet; 2011 Mar; 20(6):1154-63. PubMed ID: 21199860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
    Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
    Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.